Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company’s portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company’s web site at www.alteon.com.
- 18 years ago
QualityStocks
Synvista Therapeutics, Inc. (AMEX: SYI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Releases RoadSight UGV Demonstration Video
Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability,…